End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
15.22 CNY | -1.55% | -4.40% | -37.13% |
May. 23 | Jiuzhou Pharmaceutical Plans CRO in Germany | MT |
Apr. 24 | Zhejiang Jiuzhou Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- With a P/E ratio at 10.88 for the current year and 9.06 for next year, earnings multiples are highly attractive compared with competitors.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-37.13% | 1.89B | B- | ||
+38.51% | 727B | C+ | ||
+33.05% | 599B | B | ||
-6.23% | 354B | C+ | ||
+18.78% | 328B | B- | ||
+1.35% | 277B | C+ | ||
+16.00% | 243B | B+ | ||
+8.09% | 205B | B- | ||
-5.77% | 203B | A+ | ||
+6.19% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603456 Stock
- Ratings Zhejiang Jiuzhou Pharmaceutical Co., Ltd